2023 Guidance and Q3 Earnings

Changes since Q2 2023 Changes on pipeline New to Phase I 3915393 - · TG2 inhibitor, pulmonary fibrosis 4524101 - DNA polymerase theta inhibitor, breast cancer Achieved pipeline catalysts Regulatory decisions Arexvy - Adjuvanted recombinant protein, RSV older adults Apretude - Pre-exposure prophylaxis (PrEP) Vocabria - HIV, combination with rilpivirine long-acting injection Jemperli - RUBY, DMMR/MSI-H IL endometrial cancer Ojjaara (momelotinib) – MOMENTUM, myelofibrosis Removed from Phase I 2904545 - Recombinant protein, adjuvanted, C. difficile 4074386 Anti-LAG-3 antibody, cancer - 3745417-STING agonist, cancer Regulatory submissions & acceptances Nucala CRSWNP 1 momelotinib - SIMPLIFY-1 & MOMENTUM, myelofibrosis Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven JP 22N55 EU CN US US JP JP 22. Progressed to Phase II 4382276-mRNA, seasonal flu 4396687 mRNA, COVID-19 3993129 - Adjuvanted recombinant subunit, cytomegalovirus 3739937 - Maturation inhibitor, HIV 4004280 Capsid protein inhibitor, HIV 4011499 - Capsid protein inhibitor, HIV 1070806 Anti-IL18 antibody, atopic dermatitis 4527226 (AL-101) - Anti-sortilin antibody, Alzheimer's disease Other events Arexvy - 50-59 YoA - Positive phase III data readout bepirovirsen - B-TOGETHER phase llb data, AASLD abstract Shingrix - Positive phase III data (China) Positive CHMP opinion tebipenem - FDA SPA agreement for phase III PIVOT-PO study Jemperli - RUBY, DMMR/MSI-H IL endometrial cancer - Jemperli - RUBY part 1 OS overall population, IL endometrial cancer - Positive phase III data 39

View entire presentation